
Mean Esophageal Eosinophil Count (cells/hpf)
140
120
100
80
60
40
20
0
92.41
116.65
122.55
90.25
24.84
25.49
p < 0.0001
p < 0.0001
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 1


RPC4046 180 mg vs. Placebo
LSMD LCL UCL p-value
Overall -69.52 -90.04 -49.00 < 0.0001
Steroid-Refractory: No -54.69 -76.88 -32.50 < 0.0001
Steroid-Refractory: Yes -85.45 -125.72 -45.19 0.0001
EEsAI PRO 21-40 [mild] -118.74 -179.87 -57.61 0.0021
EEsAI PRO 41-65 [moderate] -76.49 -104.82 -48.16 < 0.0001
EEsAI PRO 66-100 [severe] -50.56 -92.03 -9.10 0.0201
DSQ <= median -55.67 -88.99 -22.34 0.0018
DSQ > median -79.59 -106.43 -52.75 < 0.0001
Years since EoE <= 5 -57.24 -81.54 -32.95 < 0.0001
Years since EoE > 5 -85.49 -123.56 -47.43 < 0.0001
Sex = Female -61.06 -85.90 -36.22 < 0.0001
Sex = Male -75.13 -103.84 -46.41 < 0.0001
-200 -150 -100 -50 0 50 100
Favors RPC4046
Favors Placebo

FIG. 2(a)


RPC4046 360 mg vs. Placebo
LSMD LCL UCL p-value
Overall -70.19 -90.45 -49.94 < 0.0001
Steroid-Refractory: No -61.81 -84.41 -39.21 < 0.0001
Steroid-Refractory: Yes -80.73 -117.13 -44.33 < 0.0001
EEsAI PRO 21-40 [mild] -101.61 -158.62 -44.61 0.0034
EEsAI PRO 41-65 [moderate] -80.58 -108.18 -52.98 < 0.0001
EEsAI PRO 66-100 [severe] -34.39 -77.31 8.54 0.1083
DSQ <= median -58.80 -91.50 -26.10 0.0009
DSQ > median -73.11 -102.05 -44.17 < 0.0001
Years since EoE <= 5 -55.63 -79.01 -32.25 < 0.0001
Years since EoE > 5 -84.46 -123.84 -45.08 0.0001
Sex = Female -63.50 -88.13 -38.87 < 0.0001
Sex = Male -73.12 -101.46 -44.77 < 0.0001
-200 -150 -100 -50 0 50 100
Favors RPC4046
Favors Placebo

FIG. 2(b)


Mean Composite Diary Score
35
30
25
20
15
10
5
0
29.44
27.63
29.03
23.11
21.93
15.30
p = 0.9959
p = 0.0733
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 3


Steroid Refractory
Not Steroid Refractory
Mean Dysphagia Symptom Composite Diary Score
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
26.9
28.5
28.8
16.1
18.8
13.9
26.9
29.3
32.7
25.6
31.0
16.9
Baseline
Week 16
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 4


Mean (SE) Change in Composite Diary Score
0
-5
-10
-15
Baseline
Week 2
Week 4
Week 8
Week 12
Week 16
p = 0.1779
p = 0.2048
p = 0.0733
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 5


Mean (SE) Change in Composite Diary Score
5
0
-5
-10
-15
Baseline
Week 2
Week 4
Week 8
Week 12
Week 16
Placebo (N=18)
RPC4046 180 mg (N=17)
RPC4046 360 mg (N=17)

FIG. 6


Mean (SE) Change in Composite Diary Score
5
0
-5
-10
-15
Baseline
Week 2
Week 4
Week 8
Week 12
Week 16
p = 0.1974
p = 0.0197
p = 0.0460
p = 0.0547
Placebo (N=16)
RPC4046 180 mg (N=14)
RPC4046 360 mg (N=17)

FIG. 7


Placebo
OBS
Mean change in DSQ score (± SD)
10
0
-10
-20
-30
*
Baseline
Week 4
Week 8
Week 12

FIG. 8


EREF Score (all features over all locations)
Mean EREF Total Score
10
9
8
7
6
5
4
3
2
1
0
9.1
7.9
9
5.3
9.4
4.8
p = 0.0004
p < 0.0001
BL
Wk16
BL
Wk16
BL
Wk16
Placebo
RPC4046 low
RPC4046 high

FIG. 9


Inflammation (over all locations)
Remodeling (over all locations)
Mean EREF Composite Score
7
6
5
4
3
2
1
0
5.4
4.8
6.3
2.6
p < 0.0001
6.3
2.6
p < 0.0001
3.7
3.1
2.7
2.7
p = 0.7524
3.1
2.2
p = 0.1522
BL Wk16
BL Wk16
BL Wk16
BL Wk16
BL Wk16
BL Wk16
Placebo
RPC4046 low
RPC4046 high

FIG. 10


Mean Peak Esophageal Eosinophil Count (cells/hpf)
0
20
40
60
80
100
120
140
105.4
131.9
139.4
104.8
28.9
31.3
p < 0.0001
p < 0.0001
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 11


Mean EESAI PRO Score
70
60
50
40
30
20
10
0
56.1
58.1
56.2
40.4
39.3
33.2
p = 0.3867 p = 0.1103
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 12


Not Steroid Refractory
Steroid Refractory
Mean EESAI PRO Score
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
58.5
55.5
52.6
39.8
30.8
27.4
59.9
57.7
56.8
51.1
38.6
39.1*
Baseline
Week 16
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 13


Mean Subject's Global Assessment of Disease Severity Score
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
5.4
5.0
5.4
3.8
2.8
2.5
p = 0.1035
p = 0.0107
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 14


Mean Clinician's Global Assessment of Disease Severity Score
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
6.4
6.7
6.1
4.6
2.9
3.2
p = 0.0094 p = 0.0352
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 15


A lot Better
A little Better
Stayed the Same
A little worse
Worse
9.1
33.3
21.2
36.4
Placebo
3.7
29.6
22.2
44.4
RPC4046 180 mg
p = 0.4094
3.2
12.9
19.4
64.5
RPC4046 360 mg
p = 0.0143

FIG. 16


Grade
Mean Adjusted Score
60.0
50.0
40.0
30.0
20.0
10.0
0.0
40.6
47.2
49.7
40.9
20.7*
19.9*
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)
Stage
Mean Adjusted Score
50.0
40.0
30.0
20.0
10.0
0.0
40.7
44.0
46.2
40.9
21.1*
19.3*
Baseline
Week 16
Placebo (N=34)
RPC4046 180 mg (N=31)
RPC4046 360 mg (N=34)

FIG. 17